People · Operator
Named in public records as an officer, director or promoter · active 2017–2024 · Other, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Evommune, Inc. | — | Other | Series D+ | $267.3M | $1.0B | 2020 |
| Vitls Inc. | — | Biotechnology | Series A | $7.2M | $15.1M | 2017 |
Gregory Moss at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Gregory Moss on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Cohen | 1 | 38 |
| Derek DiRocco | 1 | 7 |
| Eugene Bauer | 1 | 3 |
| Robert Hopfner | 1 | 3 |
| Greg Campbell | 1 | 2 |
| Greg Moss | 1 | 2 |
| Yuexin Yu | 1 | 1 |
| Janice Drew | 1 | 1 |
| Luis Pena | 1 | 1 |
| Cadell Liedtke | 1 | 1 |
| Louise Vorster | 1 | 1 |
| Werner Vorster | 1 | 1 |
| Felice Verduyn-van Weegen | 1 | 1 |
| Kyle Carver | 1 | 1 |
| Francois Beaubien | 1 | 1 |
| Benjamin McGraw | 1 | 1 |
| Jeegar Patel | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.